Mirati KRASG12D Inhibitor
reversible KRASG12D inhibitor preclinical efficacy in cancer model from SBDD around KRASG12C inhibitor MRTX1133 Mirati Therapeutics, San Diego, CA
Molecules of the Month - 2021 Molecules of the Year Nominees
- Pfizer CoV-2 MPro Inhibitor
- Arvinas ER Chimeric Degrader
- Kronos CDK9 Inhibitor
- Merck PCSK9 Inhibitors
- Mirati KRASG12D Inhibitor
- Takeda EGFRex20 Inhibitor
- Lilly GLP Molecular Glue
- RevMed KRASG12C Tricomplex Inhibitor
- Genentech mPI3Kα Degrader
- H3Bio SF3b Splicing Modulator
- BioCryst Kallikrein Inhibitor
- Genentech ER Degrader
- Pfizer CoV-2 MPro Inhibitor
- Arvinas ER Chimeric Degrader
- Kronos CDK9 Inhibitor
- Merck PCSK9 Inhibitors
- Mirati KRASG12D Inhibitor
- Takeda EGFRex20 Inhibitor
- Lilly GLP Molecular Glue
- RevMed KRASG12C Tricomplex Inhibitor
- Genentech mPI3Kα Degrader
- H3Bio SF3b Splicing Modulator
- BioCryst Kallikrein Inhibitor
- Genentech ER Degrader